← Back to Search

PET-MR Imaging with [18F]F-AraG for HIV Infection

Phase 2
Recruiting
Led By Timothy J Henrich, MD
Research Sponsored by CellSight Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Calculated creatinine clearance (CrCl) ≥60 mL/min as estimated by the Cockcroft-Gault equation: For men, (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dL x 72) = CrCl (mL/min)* For women, multiply the result by 0.85 = CrCl (mL/min)
Age >18 years
Must not have
Current HIV-related opportunistic infection such as pneumocystis pneumonia, disseminated microbacterial infection, invasive cryptococcal disease, candidal esophagitis (limited oral thrush acceptable) and cerebral toxoplasmosis
Active systemic autoimmune diseases.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-4 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial is exploring the use of a new PET tracer to study HIV in the body. It will enroll people who are early or late in their infection, or who are not on treatment.

Who is the study for?
Adults over 18 with HIV, either treated early/late or not on antiretroviral therapy (ART), can join. They must understand the consent form and meet certain health criteria like a specific platelet count, liver enzyme levels, and kidney function. People with MRI contraindications, recent immune therapies, pregnancy/breastfeeding, transplants, severe infections or illnesses within 3 months are excluded.
What is being tested?
The trial is testing [18F]F-AraG via PET-MR imaging to see where it goes in the body of HIV-infected individuals. It's an exploratory study at one center involving a single microdose of this tracer followed by whole-body scans to map its distribution.
What are the potential side effects?
[18F]F-AraG is given as a microdose for imaging purposes; therefore side effects are expected to be minimal. However, typical risks associated with intravenous injections and exposure to radiation from PET scans may include discomfort at injection site and allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney function, measured by creatinine clearance, is good.
Select...
I am older than 18 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have severe HIV-related infections like pneumonia or brain infections.
Select...
I have an active autoimmune disease.
Select...
I have a history of heart failure that needed treatment.
Select...
I am not pregnant and can be tested to confirm.
Select...
I haven't been hospitalized or needed IV antibiotics in the last 3 months.
Select...
I have been diagnosed with myelodysplasia syndrome or had lymphoproliferative disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-4 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-4 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Anatomical distribution of [18F]F-AraG
Secondary study objectives
Correlate [18F]F-AraG uptake with measures of HIV persistence
[18F]F-AraG uptake in early and later-treated HIV infection

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]F-AraGExperimental Treatment1 Intervention
radiofluorinated imaging agent, \[18F\]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) Trade name: VisAcT

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor
17 Previous Clinical Trials
293 Total Patients Enrolled
University of California, San FranciscoOTHER
2,588 Previous Clinical Trials
14,900,977 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,323 Previous Clinical Trials
5,365,144 Total Patients Enrolled

Media Library

[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) Clinical Trial Eligibility Overview. Trial Name: NCT03684655 — Phase 2
Human Immunodeficiency Virus Infection Research Study Groups: [18F]F-AraG
Human Immunodeficiency Virus Infection Clinical Trial 2023: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) Highlights & Side Effects. Trial Name: NCT03684655 — Phase 2
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03684655 — Phase 2
~4 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top